Legal status | |
---|---|
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C22H26O4 |
Molar mass | 354.446 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Vutiglabridin (HSG4112) is an experimental anti-obesity drug that is a synthetic structural analog of glabridin.
References
- Hyeon, Jooseung; Lee, Jihan; Kim, Eunju; Lee, Hyeong Min; Kim, Kwang Pyo; Shin, Jaejin; Park, Hyung Soon; Lee, Yun-Il; Nam, Chang-Hoon (October 2023). "Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions". Experimental Gerontology. 181: 112269. doi:10.1016/j.exger.2023.112269. PMID 37567452.
- Na, Joo Young; Yoon, Deok Yong; Yoo, Hyounggyoon; Lee, SeungHwan; Yu, Kyung-Sang; Jang, In-Jin; Yoo, Sang-Ku; Kim, Youngah; Oh, Jaeseong (November 2022). "Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first-in-class, first-in-human study". Clinical and Translational Science. 15 (11): 2744–2757. doi:10.1111/cts.13401. ISSN 1752-8054. PMC 9652434. PMID 36176051.
- Choi, Leo Sungwong; Jo, In Geun; Kang, Ku Suk; Im, Jeong Ho; Kim, Jiyoung; Kim, Jinyoung; Chung, Jin Wook; Yoo, Sang-Ku (January 2021). "Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity". International Journal of Obesity. 45 (1): 130–142. doi:10.1038/s41366-020-00686-1. ISSN 1476-5497. PMC 7752758. PMID 32943760.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |